1. ALLA AKTIER
  2. NYHETER
  3. FLERIE

Flerie

Nyheter Flerie Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Flerie provides update on portfolio company Provell Pharmaceuticals

Stockholm, Sweden, April 3 2025. Flerie AB announces that its portfolio company Provell Pharmaceuticals has filed for bankruptcy in the U.S. under a Chapter 7 proceeding. This does not affect Fleries's net asset value, as the company has previously written off the entire value of its holding in Provell Pharmaceuticals. Flerie's ownership in Provell Pharmaceuticals – a privately owned U.S. based specialty pharmaceutical company – amounts to 72%.

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments
Flerie provides update on portfolio company Provell Pharmaceuticals

Datum 2025-04-03, kl 14:00
Källa MFN
Bifogade filer
Flerie provides update on portfolio company Provell Pharmaceuticals